San Diego-primarily based Viking Therapeutics marked alone as a significant competitor from the weight loss drug market place in February soon after revealing promising facts from the mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection and in March t